JPWO2021037222A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021037222A5
JPWO2021037222A5 JP2022513891A JP2022513891A JPWO2021037222A5 JP WO2021037222 A5 JPWO2021037222 A5 JP WO2021037222A5 JP 2022513891 A JP2022513891 A JP 2022513891A JP 2022513891 A JP2022513891 A JP 2022513891A JP WO2021037222 A5 JPWO2021037222 A5 JP WO2021037222A5
Authority
JP
Japan
Prior art keywords
cmsd
itams
modified
itam
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513891A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547837A (ja
JP2022547837A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/112182 external-priority patent/WO2021037222A1/en
Publication of JP2022547837A publication Critical patent/JP2022547837A/ja
Publication of JPWO2021037222A5 publication Critical patent/JPWO2021037222A5/ja
Publication of JP2022547837A5 publication Critical patent/JP2022547837A5/ja
Pending legal-status Critical Current

Links

JP2022513891A 2019-08-28 2020-08-28 遺伝子操作されたt細胞及びその産生方法 Pending JP2022547837A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/103041 2019-08-28
CN2019103041 2019-08-28
CNPCT/CN2019/125681 2019-12-16
CN2019125681 2019-12-16
PCT/CN2020/112182 WO2021037222A1 (en) 2019-08-28 2020-08-28 Engineered t cells and methods of producing thereof

Publications (3)

Publication Number Publication Date
JP2022547837A JP2022547837A (ja) 2022-11-16
JPWO2021037222A5 true JPWO2021037222A5 (https=) 2023-09-01
JP2022547837A5 JP2022547837A5 (https=) 2023-09-01

Family

ID=74683378

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022513162A Pending JP2022545815A (ja) 2019-08-28 2020-08-28 Nef含有T細胞及びその産生方法
JP2022513891A Pending JP2022547837A (ja) 2019-08-28 2020-08-28 遺伝子操作されたt細胞及びその産生方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022513162A Pending JP2022545815A (ja) 2019-08-28 2020-08-28 Nef含有T細胞及びその産生方法

Country Status (12)

Country Link
US (2) US20230085615A2 (https=)
EP (2) EP4022044A4 (https=)
JP (2) JP2022545815A (https=)
KR (2) KR20230004898A (https=)
CN (3) CN119709627A (https=)
AU (2) AU2020336791A1 (https=)
CA (2) CA3152936A1 (https=)
IL (1) IL290946A (https=)
MX (1) MX2022002325A (https=)
TW (2) TW202122574A (https=)
WO (2) WO2021037222A1 (https=)
ZA (1) ZA202202127B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4282877A3 (en) 2016-08-10 2024-02-21 Legend Biotech Ireland Limited Chimeric antigen receptors targeting bcma and methods of use thereof
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
US20240226294A9 (en) * 2021-02-15 2024-07-11 H. Lee Moffitt Cancer Center And Research Institute Inc. Customized chimeric antigen receptor polypeptides
TWI863006B (zh) * 2021-10-18 2024-11-21 美商凱特製藥公司 用於嵌合抗原受體之信號傳導域
CN120344250A (zh) * 2022-10-25 2025-07-18 美商凯维那医疗公司 使用抗cd19 car-t细胞疗法治疗狼疮性肾炎的方法
WO2024153211A1 (en) * 2023-01-19 2024-07-25 Nanjing Legend Biotech Co., Ltd. Fusion polypeptides for targeted protein degradation and mehtods of use thereof
WO2024196969A2 (en) * 2023-03-20 2024-09-26 Memorial Sloan-Kettering Cancer Center Cells and compositions for treating cancer
CN121419987A (zh) * 2023-07-07 2026-01-27 南京传奇生物科技有限公司 蛋白质及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005070041A2 (en) * 2004-01-09 2005-08-04 Morehouse School Of Medicine Modulating vaccine against hiv nef protein-induced lymphocyte depletion
WO2018132506A1 (en) * 2017-01-10 2018-07-19 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
CN108395481B (zh) * 2017-02-08 2021-02-05 西比曼生物科技(香港)有限公司 一种靶向cd20的car的构建及其工程化t细胞的活性鉴定
BR112019021857A2 (pt) * 2017-04-19 2020-06-02 Allogene Therapeutics, Inc. Métodos e composições de célula t aperfeiçoada
CN109306014B (zh) * 2017-07-27 2022-04-12 上海细胞治疗研究院 一种靶向间皮素的嵌合抗原受体修饰t细胞及其用途
WO2019126358A1 (en) * 2017-12-22 2019-06-27 Cell Design Labs, Inc. Single- and multi-chain chimeric antigen receptors
SG11202006050XA (en) * 2017-12-29 2020-07-29 Memorial Sloan Kettering Cancer Center Enhanced chimeric antigen receptors and uses thereof
US20210023170A1 (en) * 2018-02-12 2021-01-28 University Of Florida Research Foundation, Incorporated Fviii chimeric antigen receptor tregs for tolerance induction in hemophilia a

Similar Documents

Publication Publication Date Title
TWI817302B (zh) 改良的雙特異性多肽分子
JP2022113880A5 (https=)
Steinle et al. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family
JP2025065142A5 (https=)
US20050261478A1 (en) Compositions and methods for regulating lymphocyte activation
US11180553B2 (en) Chimeric antigen receptor
US11198737B2 (en) T cell-antigen coupler with Y177 mutation and methods of uses thereof
KR20230095083A (ko) Cd7 표적의 키메라 항원 수용체 및 이의 용도
CN118496374A (zh) 一种抗dll3嵌合抗原受体及其用途
JP2021532742A5 (https=)
CN106699874B (zh) 识别prame抗原短肽的t细胞受体
JP2020535796A5 (https=)
JPWO2020228825A5 (https=)
KR20210021593A (ko) 다양한 구조 최적화를 갖는 t 세포-항원 커플러
JPWO2020228824A5 (https=)
JPWO2021037222A5 (https=)
DE102006041455A1 (de) Verfahren zur Verbesserung der spezifischen Effektorfunktion von Einzelketten-Antigen-erkennenden genetischen Konstrukten (scARC) durch deren Murinisierung
CN114195898B (zh) 人源化抗cd33的单域抗体及其构建体制备方法和应用
JPWO2021037221A5 (https=)
JPWO2021016585A5 (https=)
CN115521917A (zh) 工程化免疫细胞及其用途
JPWO2021091945A5 (https=)
JPWO2023143537A5 (https=)
KR20260042160A (ko) 이중특이적 폴리펩티드 분자
JPWO2023150698A5 (https=)